MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584917 | Name: Opc 3911

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Opc 3911 is a phosphodiesterase inhibitor.

Chemical Structure

Opc 3911
Opc 3911
CAS#76470-87-6

Theoretical Analysis

MedKoo Cat#: 584917

Name: Opc 3911

CAS#: 76470-87-6

Chemical Formula: C21H30N2O4

Exact Mass: 374.2206

Molecular Weight: 374.48

Elemental Analysis: C, 67.35; H, 8.08; N, 7.48; O, 17.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Opc 3911; Opc-3911; Opc3911
IUPAC/Chemical Name
Butanamide, N-cyclohexyl-N-(2-hydroxyethyl)-4-((1,2,3,4-tetrahydro-2-oxo-6-quinolinyl)oxy)-
InChi Key
OKVCJEKPURYZKG-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H30N2O4/c24-13-12-23(17-5-2-1-3-6-17)21(26)7-4-14-27-18-9-10-19-16(15-18)8-11-20(25)22-19/h9-10,15,17,24H,1-8,11-14H2,(H,22,25)
SMILES Code
O=C(N(C1CCCCC1)CCO)CCCOC2=CC3=C(NC(CC3)=O)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 374.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lindgren S, Andersson KE, Belfrage P, Degerman E, Manganiello VC. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels. Pharmacol Toxicol. 1989 May;64(5):440-5. PubMed PMID: 2549528. 2: Lindgren S, Andersson KE. Comparison of the effects of milrinone and OPC 3911 with those of isoprenaline, forskolin and dibutyryl-cAMP in rat aorta. Gen Pharmacol. 1991;22(4):617-24. PubMed PMID: 1718812. 3: Mörner SE, Arlock P, Lindgren S. The inotropic mechanism of the phosphodiesterase inhibitor OPC 3911 alone and in combination with rolipram, studied in papillary muscles of ferret and guinea-pig and isolated myocytes of guinea-pig ventricular muscle. Acta Physiol Scand. 1994 Mar;150(3):325-34. PubMed PMID: 8010139. 4: Lindgren S, Rascón A, Andersson KE, Manganiello V, Degerman E. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem Pharmacol. 1991 Jul 15;42(3):545-52. PubMed PMID: 1650216. 5: Zhao H, Quilley J, Montrose DC, Rajagopalan S, Guan Q, Smith CJ. Differential effects of phosphodiesterase PDE-3/PDE-4-specific inhibitors on vasoconstriction and cAMP-dependent vasorelaxation following balloon angioplasty. Am J Physiol Heart Circ Physiol. 2007 Jun;292(6):H2973-81. Epub 2007 Feb 9. PubMed PMID: 17293498. 6: Dicker A, Kaaman M, van Harmelen V, Aström G, Blanc KL, Rydén M. Differential function of the alpha2A-adrenoceptor and Phosphodiesterase-3B in human adipocytes of different origin. Int J Obes (Lond). 2005 Dec;29(12):1413-21. PubMed PMID: 16077714. 7: Sengenès C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000 Jul;14(10):1345-51. PubMed PMID: 10877827. 8: Lindgren SH, Andersson TL, Vinge E, Andersson KE. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels. Acta Physiol Scand. 1990 Oct;140(2):209-19. PubMed PMID: 2176433. 9: Eriksson JW, Wesslau C, Smith U. The cGMP-inhibitable phosphodiesterase modulates glucose transport activation by insulin. Biochim Biophys Acta. 1994 Jan 19;1189(2):163-7. PubMed PMID: 8292620. 10: Meacci E, Taira M, Moos M Jr, Smith CJ, Movsesian MA, Degerman E, Belfrage P, Manganiello V. Molecular cloning and expression of human myocardial cGMP-inhibited cAMP phosphodiesterase. Proc Natl Acad Sci U S A. 1992 May 1;89(9):3721-5. PubMed PMID: 1315035; PubMed Central PMCID: PMC525562. 11: Lindgren S, Andersson KE. Effects of selective phosphodiesterase inhibitors on isolated coronary, lung and renal arteries from man and rat. Acta Physiol Scand. 1991 May;142(1):77-82. PubMed PMID: 1652182. 12: Eriksson H, Ridderstråle M, Degerman E, Ekholm D, Smith CJ, Manganiello VC, Belfrage P, Tornqvist H. Evidence for the key role of the adipocyte cGMP-inhibited cAMP phosphodiesterase in the antilipolytic action of insulin. Biochim Biophys Acta. 1995 Apr 6;1266(1):101-7. PubMed PMID: 7718614. 13: Zmuda-Trzebiatowska E, Oknianska A, Manganiello V, Degerman E. Role of PDE3B in insulin-induced glucose uptake, GLUT-4 translocation and lipogenesis in primary rat adipocytes. Cell Signal. 2006 Mar;18(3):382-90. Epub 2005 Jun 14. PubMed PMID: 15961276. 14: Degerman E, Moos M Jr, Rascón A, Vasta V, Meacci E, Smith CJ, Lindgren S, Andersson KE, Belfrage P, Manganiello V. Single-step affinity purification, partial structure and properties of human platelet cGMP inhibited cAMP phosphodiesterase. Biochim Biophys Acta. 1994 Apr 13;1205(2):189-98. PubMed PMID: 8155697. 15: Movsesian MA, Smith CJ, Krall J, Bristow MR, Manganiello VC. Sarcoplasmic reticulum-associated cyclic adenosine 5'-monophosphate phosphodiesterase activity in normal and failing human hearts. J Clin Invest. 1991 Jul;88(1):15-9. PubMed PMID: 1647414; PubMed Central PMCID: PMC295996. 16: Rascón A, Lindgren S, Stavenow L, Belfrage P, Andersson KE, Manganiello VC, Degerman E. Purification and properties of the cGMP-inhibited cAMP phosphodiesterase from bovine aortic smooth muscle. Biochim Biophys Acta. 1992 Mar 16;1134(2):149-56. PubMed PMID: 1313303. 17: Dolgacheva LP, Abzhalelov BB, Zhang SJ, Zinchenko VP, Bronnikov GE. Norepinephrine induces slow calcium signalling in murine brown preadipocytes through the beta-adrenoceptor/cAMP/protein kinase A pathway. Cell Signal. 2003 Feb;15(2):209-16. PubMed PMID: 12464392. 18: Rascón A, Viloria ME, De-Chiara L, Dubra ME. Characterization of cyclic AMP phosphodiesterases in Leishmania mexicana and purification of a soluble form. Mol Biochem Parasitol. 2000 Mar 5;106(2):283-92. PubMed PMID: 10699257. 19: Leroy MJ, Degerman E, Taira M, Murata T, Wang LH, Movsesian MA, Meacci E, Manganiello VC. Characterization of two recombinant PDE3 (cGMP-inhibited cyclic nucleotide phosphodiesterase) isoforms, RcGIP1 and HcGIP2, expressed in NIH 3006 murine fibroblasts and Sf9 insect cells. Biochemistry. 1996 Aug 6;35(31):10194-202. PubMed PMID: 8756484. 20: Wesslau C, Eriksson JW, Smith U. Cellular cyclic AMP levels modulate insulin sensitivity and responsiveness--evidence against a significant role of Gi in insulin signal transduction. Biochem Biophys Res Commun. 1993 Oct 15;196(1):287-93. PubMed PMID: 8216302.